121125-49-3

Basic information

• Product Name: <<(1,4-dihydro-1-methyl-3-pyridinyl)carbonyl>oxy>methyl <2S-(2α,5α,6β)>-3,3-dimethyl-7-oxo-6-<(phenylacetyl)amino>-4-thia-1-azabicyclo<3.2.0>heptane-2-carboxylate
• Synonyms: <<(1,4-dihydro-1-methyl-3-pyridinyl)carbonyl>oxy>methyl <2S-(2α,5α,6β)>-3,3-dimethyl-7-oxo-6-<(phenylacetyl)amino>-4-thia-1-azabicyclo<3.2.0>heptane-2-carboxylate
• CAS NO: 121125-49-3
• Molecular Weight: 485.561
• Mol File: 121125-49-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: <<(1,4-dihydro-1-methyl-3-pyridinyl)carbonyl>oxy>methyl <2S-(2α,5α,6β)>-3,3-dimethyl-7-oxo-6-<(phenylacetyl)amino>-4-thia-1-azabicyclo<3.2.0>heptane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: <<(1,4-dihydro-1-methyl-3-pyridinyl)carbonyl>oxy>methyl <2S-(2α,5α,6β)>-3,3-dimethyl-7-oxo-6-<(phenylacetyl)amino>-4-thia-1-azabicyclo<3.2.0>heptane-2-carboxylate(121125-49-3)
• EPA Substance Registry System: <<(1,4-dihydro-1-methyl-3-pyridinyl)carbonyl>oxy>methyl <2S-(2α,5α,6β)>-3,3-dimethyl-7-oxo-6-<(phenylacetyl)amino>-4-thia-1-azabicyclo<3.2.0>heptane-2-carboxylate(121125-49-3)

Safety Data

• Hazardous Substances Data: 121125-49-3(Hazardous Substances Data)

Upstream product

• 122048-10-6 <(3-pyridinylcarbonyl)oxy>methyl <2S-(2α,5α,6β)>-3,3-dimethyl-7-oxo-6-<(phenylacetyl)amino>-4-thia-1-azabicyclo<3.2.0>heptane-2-carboxylate 
• 34573-47-2 chloromethyl <2S-(2α,5α,6β)>-3,3-dimethyl-7-oxo-6-<(phenylacetyl)amino>-4-thia-1-azabicyclo<3.2.0>heptane-2-carboxylate 
• 16518-17-5 potassium nicotinate 
• 121125-45-9 <2S-(2α,5α,6β)>-3-<<<<<3,3-dimethyl-7-oxo-6-<(phenylacetyl)amino>-4-thia-1-azabicyclo<3.2.0>hept-2-yl>carbonyl>oxy>methoxy>carbonyl>-1-methylpyridinium iodide 

Downstream Products

• 121125-45-9 <2S-(2α,5α,6β)>-3-<<<<<3,3-dimethyl-7-oxo-6-<(phenylacetyl)amino>-4-thia-1-azabicyclo<3.2.0>hept-2-yl>carbonyl>oxy>methoxy>carbonyl>-1-methylpyridinium iodide 

Relevant articles and documents

Pharmaceutical formulations for parenteral use

Aqueous parenteral solutions of drugs which are insoluble or only sparingly soluble in water and/or which are unstable in water, combined with cyclodextrin selected from the group consisting of hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of β- and γ-cyclodextrin, provide a means for alleviating problems associated with drug precipitation at the injection site and/or in the lungs or other organs following parenteral administration.